ArticleBMC women's health2025
Evaluation of anemia and iron status in Japanese patients with gynecological malignancy: retrospective cohort study
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia and iron deficiency are common among patients with cancer and can have a significant impact on their prognosis. However, the current status of anemia and iron deficiency in Japanese patients with gynecological malignancies remains unclear. This study aimed to clarify the prevalence of anemia and iron deficiency at the time of diagnosis and to evaluate their influence on hemoglobin levels during cancer treatment in Japanese patients with gynecological malignancies.
methodsEligible patients were those diagnosed with gynecological cancers. Anemia and iron status were evaluated before and within 6 months of initiating cancer treatments at our institution between January 2022 and July 2024. Statistical comparison of risk factors was performed with the Mann-Whitney U test, Student t-test, and one-way analysis of variance. Iron status and transferrin saturation (TSAT) were classified using the National Comprehensive Cancer Network guidelines.
resultsA total of 103 patients were assessed for eligibility. The median (interquartile range) hemoglobin level was 12.5 (10.6-13.2) g/dL, and 29.1% of patients had hemoglobin ≤ 11.0 g/dL before cancer treatment. TSAT < 20% and < 50% accounted for 46.7% and 99.0% of patients, respectively; 9.9% and 11.1% were classified as having absolute and functional iron deficiency anemia, respectively. Sixty-two patients received chemotherapy or concurrent chemoradiotherapy for their cancers, and 90.3% developed anemia within 6 months of initiation of treatment. Lower hemoglobin and serum ferritin before treatment, as well as hemoglobin at its lowest point within 6 months of treatment, were found in patients with TSAT < 20%.
conclusionsAnemia and iron deficiency were prevalent among Japanese patients with gynecological cancers. TSAT < 20% before treatment was associated with more severe anemia during treatment. TSAT may be a useful biomarker for predicting and managing treatment-related anemia. Early intervention based on TSAT levels could help maintain hemoglobin levels and prevent treatment interruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.